ReviewInternational immunopharmacology2020
Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses.
Review in International immunopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Coronavirus (SARS-CoV-2): a systematic review for potential vaccines.Human vaccines & immunotherapeutics · 2022Pooled it
- The effect of influenza vaccine in reducing the severity of clinical outcomes in patients with COVID-19: a systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review.Journal of medical virology · 2021Pooled it
- Article
- Progress in combination vaccines and the co-administration of influenza virus and SARS-CoV-2 vaccines.Frontiers in immunology · 2025Review
- The Development of Epitope-Based Recombinant Protein Vaccines against SARS-CoV-2.The AAPS journal · 2024Review
- 30-Year Development of Inactivated Virus Vaccine in China.Pharmaceutics · 2023Review
- Recent advances in respiratory immunization: A focus on COVID-19 vaccines.Journal of controlled release : official journal of the Controlled Release Society · 2023Review
- CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2.PloS one · 2023Article
- The impact of influenza vaccination on surgical outcomes in COVID-19 positive patients: An analysis of 43,580 patients.PloS one · 2023Article
- A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2022Review
- Influenza and pneumococcal vaccination and COVID-19 in kidney transplant patients.Transplant immunology · 2022Article
- Vaccines platforms and COVID-19: what you need to know.Tropical diseases, travel medicine and vaccines · 2022Review
- A Precision Adjuvant Approach to Enhance Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines Optimized for Immunologically Distinct Vulnerable Populations.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters.Scientific reports · 2022Article
- Mechanistic understanding of the aspect ratio-dependent adjuvanticity of engineered aluminum oxyhydroxide nanorods in prophylactic vaccines.Nano today · 2022Article
- Thyroid as a target of adjuvant autoimmunity/inflammatory syndrome due to mRNA-based SARS-CoV2 vaccination: from Graves' disease to silent thyroiditis.Journal of endocrinological investigation · 2022Review
- Innovative adjuvant augments potency of a SARS-CoV-2 subunit vaccine.Cell research · 2022Article
- Vaccines Against COVID-19: A Review.Vaccines · 2022Review
- Influenza vaccination and prognosis for COVID-19 in hospitalized patients with diabetes: Results from the CORONADO study.Diabetes, obesity & metabolism · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The extensive efforts around the globe are being made to develop a suitable vaccine against COVID-19 (Coronavirus Disease-19) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). An effective vaccine should be able to induce high titers of neutralizing antibodies to prevent the virus from attaching to the host cell receptors. However, to elicit the protective levels of antibodies, a vaccine may require multiple doses or assistance from other immunostimulatory molecules. Further, the vaccine should be able to induce protective levels of antibodies rapidly with the least amount of antigen used. This decreases the cost of a vaccine and makes it affordable. As the pandemic has hit most countries across the globe, there will be an overwhelming demand for the vaccine in a quick time. Incorporating a suitable adjuvant in a SARS-CoV-2 vaccine may address these requirements. This review paper will discuss the experimental results of the adjuvanted vaccine studies with similar coronaviruses (CoVs) which might be useful to select an appropriate adjuvant for a vaccine against rapidly emergingSARS-CoV-2. We also discuss the current progress in the development of adjuvanted vaccines against the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.